Ncs Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 23-10-2024
- Paid Up Capital ₹ 4.85 M
as on 23-10-2024
- Company Age 27 Year, 29 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 13.17 Cr
as on 23-10-2024
- Revenue 10.84%
(FY 2023)
- Profit 514.07%
(FY 2023)
- Ebitda 68.17%
(FY 2023)
- Net Worth 312.99%
(FY 2023)
- Total Assets 93.81%
(FY 2023)
About Ncs Diagnostics
The Corporate was formerly known as Eastersn Fertility & Genetic Research Center Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 4.85 M.
The company currently has active open charges totaling ₹13.17 Cr.
Kamal Oswal and Poonam Rathore serve as directors at the Company.
- CIN/LLPIN
U24231WB1997PTC085984
- Company No.
085984
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Nov 1997
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ncs Diagnostics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamal Oswal  | Director | 04-Jan-1999 | Current |
| Poonam Rathore | Director | 08-Apr-2023 | Current |
Financial Performance of Ncs Diagnostics.
Ncs Diagnostics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 10.84% increase. The company also saw a substantial improvement in profitability, with a 514.07% increase in profit. The company's net worth Soared by an impressive increase of 312.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ncs Diagnostics?
In 2023, Ncs Diagnostics had a promoter holding of 85.51% and a public holding of 14.49%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 26 Sep 2024 | ₹1.52 Cr | Open |
Hdfc Bank Limited Creation Date: 21 Aug 2024 | ₹0.86 M | Open |
Hdfc Bank Limited Creation Date: 27 Mar 2024 | ₹1.33 Cr | Open |
How Many Employees Work at Ncs Diagnostics?
Ncs Diagnostics has a workforce of 22 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ncs Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ncs Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
